FDA Reviewers: Why We Are Against Approval of Aducanumab for Alzheimer’s

By |2021-05-06T09:35:36-07:00May 6th, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|

Three members of a US Food and Drug Administration (FDA) advisory committee are explaining why they do not support approval of the drug aducanumab (Biogen, Eisai) for the treatment of Alzheimer's disease (AD). G. Caleb Alexander, MD, Scott Emerson, MD, PhD, and Aaron Kesselheim, MD, JD, MPH, all serve on the [...]

Novel Drug Offers Rapid Relief From Agitation in Serious Mental Illness

By |2021-05-06T09:36:50-07:00May 6th, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|

An investigational, orally dissolving film formulation of dexmedetomidine (BXCL501, BioXcel Therapeutics) may offer rapid relief from acute agitation related to schizophrenia or bipolar disorder (BD), results of two phase 3, randomized, placebo-controlled trials show. Dr Leslie Citrome For both disorders, BXCL501 showed "superiority over placebo" by meeting the primary endpoint of reduction of agitation as [...]

Associations between breast cancer survivorship and adverse mental health outcomes: A matched population-based cohort study in the United Kingdom

By |2021-01-19T12:45:20-08:00January 19th, 2021|Brief Bulletins from the Field, We Know Psychiatry|

SUMMARY In this study, we observed that compared to women with no prior cancer, breast cancer survivors had higher risk of anxiety, depression, sleep problems, sexual dysfunction, fatigue, receipt of opioid analgesics, and pain. Relative risks estimates tended to decrease over time, but anxiety and depression were significantly increased for [...]

Suicide Prevention in the COVID-19 Era Transforming Threat Into Opportunity

By |2020-10-20T09:07:02-07:00October 20th, 2020|Brief Bulletins from the Field, We Know Psychiatry|

From: JAMA Psychiatry. Published online October 16, 2020. doi:10.1001/jamapsychiatry.2020.3746 By Christine Moutier, MD Introduction International and US experts on suicide have expressed concerns about the potential the coronavirus disease 2019 (COVID-19) pandemic has to increase the risk of suicide through its effects on a number of well-established suicide risk factors.1,2 Suicide surveillance [...]

A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms

By |2020-07-29T09:04:39-07:00July 29th, 2020|Brief Bulletins from the Field|

The current maintenance treatment for opiate withdrawal usually includes using a different, controlled, opiate, either methadone or buprenorphine. Alpha-2 receptor agonists, such as lofexidine, can be used to manage the acute symptoms during withdrawal. Lofexidine is effective and safe and is FDA approved for the management of withdrawal symptoms. It [...]

Naldemedine for the Use of Management of Opioid Induced Constipation

By |2020-07-29T08:59:49-07:00July 29th, 2020|Brief Bulletins from the Field|

According to Urits and Viswanath, Opioid medications are fundamental in anesthesia and analgesia and are often used to treat acute and chronic pain. They achieve their desired effects by modulating pain perception in the central nervous system; however, they also act on opioid receptors in the periphery, causing many undesirable [...]

Antiepileptic Drugs and Bone Health: Current Concepts

By |2020-06-04T10:53:56-07:00June 4th, 2020|Brief Bulletins from the Field, We Know Psychiatry|

Chronic use of antiepileptic drugs (AEDs) can induce the development of adverse effects on bone metabolism. In epileptic patients treated with AED, the monitor- ing of biochemical markers of bone turnover, such as the measurement of serum 25 (OH) vitamin D, bone mineral density, before the beginning of the treatment [...]

Title

Go to Top